Research Overview of Suprax-DT 400
Suprax-DT 400 Eczacibasi is a cephalosporin antibiotic formulation manufactured by Eczacibasi pharmaceutical company for controlled laboratory research applications. This dispersible tablet formulation contains cefixime as the active compound, belonging to the third-generation cephalosporin class of beta-lactam antibiotics. Researchers studying antimicrobial mechanisms and bacterial resistance patterns can investigate this compound’s molecular interactions within controlled experimental protocols. The dispersible tablet format facilitates consistent preparation of research solutions at precise concentrations for in-vitro bacterial culture studies.
Laboratory investigators examining antibiotic mechanisms often require standardised formulations from established pharmaceutical manufacturers to ensure reproducible experimental outcomes. Suprax-DT 400 provides researchers with access to a clinically-relevant cephalosporin formulation for comparative studies with other beta-lactam antibiotics. Scientists at Stroid UK Shop can source this compound alongside other research chemicals for comprehensive antimicrobial research programmes.
Research Applications in Laboratory Studies
Cefixime research applications encompass multiple areas of microbiological and pharmaceutical investigation. Researchers studying bacterial cell wall synthesis can examine how this third-generation cephalosporin inhibits penicillin-binding proteins in controlled bacterial cultures. The compound’s broad-spectrum activity makes it valuable for comparative efficacy studies against gram-positive and gram-negative bacterial strains under standardised laboratory conditions.
Pharmaceutical researchers investigating antibiotic resistance mechanisms can utilise Suprax-DT 400 in studies examining beta-lactamase enzyme interactions and resistance gene expression patterns. The dispersible formulation enables precise dosing in bacterial sensitivity assays and minimum inhibitory concentration determinations. Research institutions studying cephalosporin compounds often require multiple antibiotic formulations for comprehensive antimicrobial spectrum analysis.
Pharmacokinetic researchers can investigate absorption and stability characteristics of the dispersible tablet formulation compared to standard oral preparations. Studies examining bioavailability enhancement through tablet disintegration profiles provide insights into pharmaceutical formulation optimisation. Researchers working with selective research compounds may incorporate antibiotic controls in cellular viability assays. Scientists studying compound interactions often source diverse research chemicals including peptide modulators for comprehensive experimental protocols.
Compound Specifications and Properties
| Parameter | Specification |
|---|---|
| Active Compound | Cefixime |
| Formulation | Dispersible Tablet |
| Strength | 400mg |
| Manufacturer | Eczacibasi |
| Chemical Class | Third-generation Cephalosporin |
| CAS Number | Verify with supplier |
| Molecular Formula | Verify with supplier |
| Storage Conditions | Room temperature, dry environment |
Research Compliance and Laboratory Use
Suprax-DT 400 Eczacibasi is supplied exclusively for in-vitro laboratory research applications and is not intended for human consumption or therapeutic use. Researchers must ensure compliance with institutional biosafety protocols when handling antimicrobial compounds in laboratory environments. This product is designated for qualified research institutions conducting controlled studies under appropriate ethical oversight and regulatory compliance frameworks.
